CoChat
Sign Up
Cited by 524Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice

Open access
Pan-Montojo, Francisco, Anichtchik, Oleg, Dening, Yanina, Knels, Lilla, Pursche, Stefan, Jung, Roland, Jackson, Sandra, Gille, Gabriele, Spillantini, Maria Grazia, Reichmann, Heinz, Funk, Richard H. W.·2010·PLoS ONE
DOI 10.1371/journal.pone.0008762PMC PMC2808242
Open this paper in CoChat — free accountOpen PDF

Abstract

In patients with Parkinson's disease (PD), the associated pathology follows a characteristic pattern involving inter alia the enteric nervous system (ENS), the dorsal motor nucleus of the vagus (DMV), the intermediolateral nucleus of the spinal cord and the substantia nigra, providing the basis for the neuropathological staging of the disease. Here we report that intragastrically administered rotenone, a commonly used pesticide that inhibits Complex I of the mitochondrial respiratory chain, is able to reproduce PD pathological staging as found in patients. Our results show that low doses of chronically and intragastrically administered rotenone induce alpha-synuclein accumulation in all the above-mentioned nervous system structures of wild-type mice. Moreover, we also observed inflammation and alpha-synuclein phosphorylation in the ENS and DMV. HPLC analysis showed no rotenone levels in the systemic blood or the central nervous system (detection limit [rotenone]<20 nM) and mitochondrial Complex I measurements showed no systemic Complex I inhibition after 1.5 months of treatment. These alterations are sequential, appearing only in synaptically connected nervous structures, treatment time-dependent and accompanied by inflammatory signs and motor dysfunctions. These results strongly suggest that the local effect of pesticides on the ENS might be sufficient to induce PD-like progression and to reproduce the neuroanatomical and neurochemical features of PD staging. It provides new insight into how environmental factors could trigger PD and suggests a transsynaptic mechanism by which PD might spread throughout the central nervous system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0008762

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Locally administered rotenone induces alpha-synuclein phosphorylation, accumulation and aggregation with gliosis in ENS ganglia. (scale bars 20 µm). A, B, C, anti βIII-tubulin, alpha-synuclein and DAPI staining in duodenum (B) and ileum (A,C) sections. Arrow in B, 1.5 months treatment induced an increased alpha-synuclein punctate pattern inside enteric nervous system ganglia when compared to 3 months controls (A). Arrow in C, 3 months treatment induced formation of larger alpha-synuclein inclusions (|>6 µm). D, immunofluorescence staining using anti-alpha-synuclein, Thioflavine S and DAPI. Arrow in D, only 3 month treated mice showed aggregation of these larger alpha-synuclein accumulations. E, F, quantification of the experiment shown in A–C was made using automatic segmentation and entropy-based thresholding methods. Single-asterisk, P<0.05, and double-asterisk, P<0.01. E, each column represents total alpha-synuclein surface/ganglion surface. F, each column represents total number of alpha-synuclein inclusions/ganglion surface. All graphs show mean ± s.e.m. G, H, max-projection of staining against GFAP, alpha-synuclein and DAPI on duodenum sections from control (G) and treated (H) mice. I, J, max-projection of anti-βIII-tubulin, anti-phospho-alpha-synuclein (Ser 129) and DAPI staining on duodenum sections from control (I) and treated (J) animals.
Figure 1 Locally administered rotenone induces alpha-synuclein phosphorylation, accumulation and aggregation with gliosis in ENS ganglia. (scale bars 20 µm). A, B, C, anti βIII-tubulin, alpha-synuclein and DAPI staining in duodenum (B) and ileum (A,C) sections. Arrow in B, 1.5 months treatment induced an increased alpha-synuclein punctate pattern inside enteric nervous system ganglia when compared to 3 months controls (A). Arrow in C, 3 months treatment induced formation of larger alpha-synuclein inclusions (|>6 µm). D, immunofluorescence staining using anti-alpha-synuclein, Thioflavine S and DAPI. Arrow in D, only 3 month treated mice showed aggregation of these larger alpha-synuclein accumulations. E, F, quantification of the experiment shown in A–C was made using automatic segmentation and entropy-based thresholding methods. Single-asterisk, P<0.05, and double-asterisk, P<0.01. E, each column represents total alpha-synuclein surface/ganglion surface. F, each column represents total number of alpha-synuclein inclusions/ganglion surface. All graphs show mean ± s.e.m. G, H, max-projection of staining against GFAP, alpha-synuclein and DAPI on duodenum sections from control (G) and treated (H) mice. I, J, max-projection of anti-βIII-tubulin, anti-phospho-alpha-synuclein (Ser 129) and DAPI staining on duodenum sections from control (I) and treated (J) animals.CC BY · PubMed Central
Figure 2 Intracellular and axonal alpha-synuclein increases in the intermediolateral nucleus and the dorsal horn lamina I layer of the spinal cord after oral rotenone treatment. (scale bars 20 µm) A, B, C, Immunostaining against alpha-synuclein and choline acetyl transferase (ChAT) in spinal cord sections showing the intermediolateral nucleus ChAT+ neurons from 3 months control mice (A), 1.5 months (B) and 3 months (C) treated mice. Arrow in B, colocalization of increased intracellular alpha-synuclein and ChAT+ stainings in the IML. Arrow in C, large alpha-synuclein inclusion (|>7.5 µm) inside an IML ChAT+ neuron. D–E, fluorescence intensity color-coded images from 3 months control (D, D') and 3 months treated mice (E, E') spinal cord sections stained using DAPI and alpha-synuclein and ChAT antibodies. Arrows in D and E, areas in the proximity of ChAT+ neurons. F, mean fluorescence quantification of experiment shown in D and E. Double asterisk, P<0,01. Columns represent mean alpha-synuclein fluorescence in and around ChAT+ neurons in the IML/mean alpha-synuclein fluorescence in the region anterior to the IML. Graph shows mean ± s.e.m.. G, H, DAB-staining against apha-synuclein using synuclein-1 antibody in the dorsal horn of the spinal cord from 3 months treated (H) and control (G) mice. Arrows in G–H, lamina I layer of the dorsal horn.
Figure 2 Intracellular and axonal alpha-synuclein increases in the intermediolateral nucleus and the dorsal horn lamina I layer of the spinal cord after oral rotenone treatment. (scale bars 20 µm) A, B, C, Immunostaining against alpha-synuclein and choline acetyl transferase (ChAT) in spinal cord sections showing the intermediolateral nucleus ChAT+ neurons from 3 months control mice (A), 1.5 months (B) and 3 months (C) treated mice. Arrow in B, colocalization of increased intracellular alpha-synuclein and ChAT+ stainings in the IML. Arrow in C, large alpha-synuclein inclusion (|>7.5 µm) inside an IML ChAT+ neuron. D–E, fluorescence intensity color-coded images from 3 months control (D, D') and 3 months treated mice (E, E') spinal cord sections stained using DAPI and alpha-synuclein and ChAT antibodies. Arrows in D and E, areas in the proximity of ChAT+ neurons. F, mean fluorescence quantification of experiment shown in D and E. Double asterisk, P<0,01. Columns represent mean alpha-synuclein fluorescence in and around ChAT+ neurons in the IML/mean alpha-synuclein fluorescence in the region anterior to the IML. Graph shows mean ± s.e.m.. G, H, DAB-staining against apha-synuclein using synuclein-1 antibody in the dorsal horn of the spinal cord from 3 months treated (H) and control (G) mice. Arrows in G–H, lamina I layer of the dorsal horn.CC BY · PubMed Central
Figure 3 Intragastrically administered rotenone induces alpha-synuclein accumulation, oxidative stress and inflammation in the dorsal motor nucleus vagus. (scale bars 20 µm). A, B, double-immunofluorescence staining against alpha-synuclein and ChAT on DMV sections from 1.5 months control (A) and 1.5 months treated (B) mice. Arrows in B, increased intracellular alpha-synuclein in DMV neurons already after 1.5 months. Arrowheads in B, autofluorescent punctate inclusion pattern inside ChAT+ neurons. C, DMV sections stained with ChAT and DAPI were sequentially excited with 488 and 561 laser wavelengths. Arrows in C, large intracellular auto-fluorescent inclusions inside ChAT+ neurons of the DMV (arrows). D, E, F, Light microscopy images of alpha-synuclein staining from 1.5 months control (D), 1.5 months (E) and 3 months (F) treated mice. Arrows in E and F, increased staining intensity inside DMV neuronal soma in treated mice. Arrowheads in F, increased alpha-synuclein staining inside neuronal processes G, H, average-projection of triple-immunofluorescence staining against ChAT, GFAP, MHC II (clone M5/114.15.2) and DAPI on sections from control (G) and treated (H) mice after 3 month treatment. Arrow in H, activated microglial cell in the DMV.
Figure 3 Intragastrically administered rotenone induces alpha-synuclein accumulation, oxidative stress and inflammation in the dorsal motor nucleus vagus. (scale bars 20 µm). A, B, double-immunofluorescence staining against alpha-synuclein and ChAT on DMV sections from 1.5 months control (A) and 1.5 months treated (B) mice. Arrows in B, increased intracellular alpha-synuclein in DMV neurons already after 1.5 months. Arrowheads in B, autofluorescent punctate inclusion pattern inside ChAT+ neurons. C, DMV sections stained with ChAT and DAPI were sequentially excited with 488 and 561 laser wavelengths. Arrows in C, large intracellular auto-fluorescent inclusions inside ChAT+ neurons of the DMV (arrows). D, E, F, Light microscopy images of alpha-synuclein staining from 1.5 months control (D), 1.5 months (E) and 3 months (F) treated mice. Arrows in E and F, increased staining intensity inside DMV neuronal soma in treated mice. Arrowheads in F, increased alpha-synuclein staining inside neuronal processes G, H, average-projection of triple-immunofluorescence staining against ChAT, GFAP, MHC II (clone M5/114.15.2) and DAPI on sections from control (G) and treated (H) mice after 3 month treatment. Arrow in H, activated microglial cell in the DMV.CC BY · PubMed Central
Figure 4 Alpha-synuclein accumulation and neuronal loss in the SNc after 3 but not 1.5 months intragastrical rotenone treatment. (A–C, scale bars 20 µm; E–F, scale bars 200 µm). A, B, C, immunostaining against TH, alpha-synuclein and DAPI on SNc sections from 1.5 months control (A) and 3 months (B–C) treated mice. Arrow in B, alpha-synuclein small inclusions inside TH+ neurons. Arrow in C, large alpha-synuclein inclusion (|>8.14 µm) inside a dopamineric neuron in the SN. D, stereological quantification (n = 3) of TH+ neurons in the SN from control and treated mice. Asterisk, P<0.05. Number of neurons was determined based on the optical fractionator principle using StereoInvestigator software (MicroBrightField Inc., Williston, USA). Each column represents total number of TH+ neurons in the SN in 1.5 and 3 months control and treated mice. Graph shows mean ± s.e.m. E, F, TH immunostaining on striatum in 1.5 months control (E) and 3 months treated (F) mice.
Figure 4 Alpha-synuclein accumulation and neuronal loss in the SNc after 3 but not 1.5 months intragastrical rotenone treatment. (A–C, scale bars 20 µm; E–F, scale bars 200 µm). A, B, C, immunostaining against TH, alpha-synuclein and DAPI on SNc sections from 1.5 months control (A) and 3 months (B–C) treated mice. Arrow in B, alpha-synuclein small inclusions inside TH+ neurons. Arrow in C, large alpha-synuclein inclusion (|>8.14 µm) inside a dopamineric neuron in the SN. D, stereological quantification (n = 3) of TH+ neurons in the SN from control and treated mice. Asterisk, P<0.05. Number of neurons was determined based on the optical fractionator principle using StereoInvestigator software (MicroBrightField Inc., Williston, USA). Each column represents total number of TH+ neurons in the SN in 1.5 and 3 months control and treated mice. Graph shows mean ± s.e.m. E, F, TH immunostaining on striatum in 1.5 months control (E) and 3 months treated (F) mice.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., & Funk, R. H. W.
Affiliations
  • Max Planck Institute of Molecular Cell Biology and Genetics (DE)
  • University of Cambridge (GB)
  • Technische Universität Dresden (DE)
Corresponding author
  • Pan-Montojo, Francisco
  • Funk, Richard H. W.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2010-01-19
Volume
5
Issue
1
Pages
e8762
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0008762
PMC
PMC2808242
OpenAlex
W2293877091
Cited by
524
References
64
Citations by year
2026: 12 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 40 · 2021: 43 · 2020: 41 · 2019: 46 · 2018: 31 · 2017: 44 · 2016: 35 · 2015: 32 · 2014: 33 · 2013: 29 · 2012: 37
FWCI
18.13
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Parkinson's UK (G-0701)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Parkinson's disease, rotenone, intragastric administration, alpha-synuclein accumulation, enteric nervous system, dorsal motor nucleus of the vagus, intermediolateral nucleus, substantia nigra, mitochondrial complex I inhibition, neuroinflammation, alpha-synuclein phosphorylation, pesticide exposure, disease staging, motor impairment, mouse model
MeSH terms
Animals, Chromatography, High Pressure Liquid, Disease Models, Animal, Mice, Inbred BALB C, Parkinson Disease, Rotenone, Stomach, Enteric Nervous System, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review